CD19 and neoplasm: While such an approach did lead to B-cell depletion and signs of cytokine release syndrome (CRS), the utilization of CD4 lentiviral vectors led to the production of anti-CD-19 CD4+ CAR T cells that led to more efficient tumor cell killing activity (76).